Is statin use safe in individuals with psychotic disorders?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2008-09-30

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.4088/JCP.V69N0919APMID 19193350
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.

  2008cited by this paper
• Serum lipid levels and suicidality among male patients with schizoaffective disorder.

  2008cited by this paper
• Suicide by charcoal burning in Taiwan: implications for means substitution by a case-linkage study

  2008cited by this paper
• What was retained? The assessment of the training for the peer trainers' course on short and long term basis

  2008cited by this paper
• Statins for primary prevention of coronary artery disease.

  2007cited by this paper
• Violent behavior associated with hypocholesterolemia due to a novel APOB gene mutation

  2007cited by this paper
• The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats.

  2007cited by this paper
• Charcoal burning suicides in Hong Kong and urban Taiwan: an illustration of the impact of a novel suicide method on overall regional rates

  2007cited by this paper
• Charcoal-Burning Suicides and Strategies for Prevention.

  2007cited by this paper
• Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia

  2007cited by this paper
• Mind Your Manners: Quality of Manner of Death Certification Among Medical Examiners and Coroners in Taiwan

  2006cited by this paper
• Pharmacokinetics of the plant‐derived κ‐opioid hallucinogen salvinorin A in nonhuman primates

  2005cited by this paper
• Charcoal-burning suicide in post-transition Hong Kong

  2005cited by this paper
• Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates.

  2005cited by this paper
• The role of lifestyle interventions and weight management in schizophrenia

  2005cited by this paper
• Use of nonprohibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage).

  2005cited by this paper
• Cholesterol metabolism and suicidality in Smith-Lemli-Opitz syndrome carriers.

  2004cited by this paper
• Severe irritability associated with statin cholesterol-lowering drugs.

  2004cited by this paper
• Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.

  2003cited by this paper
• Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.

  2002cited by this paper
• Serum cholesterol levels and suicide: a meta-analysis.

  2002cited by this paper
• Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist

  2002cited by this paper
• Hallucinogens on the Internet: a vast new source of underground drug information.

  2001cited by this paper
• Total serum cholesterol in relation to psychological correlates in parasuicide.

  2000cited by this paper
• Salvia divinorum: an hallucinogenic mint which might become a new recreational drug in Switzerland.

  2000cited by this paper
• Causes of the excess mortality of schizophrenia.

  2000cited by this paper
• Low cholesterol and violent crime.

  2000cited by this paper
• Cholesterol and violent behavior.

  1994cited by this paper
• Serum cholesterol in aggressive conduct disorder: a preliminary study.

  1984cited by this paper
• A New Mexican Psychotropic Drug from the Mint Family

  1962cited by this paper

• Association between Serum Lipids and Antipsychotic Response in Schizophrenia

  2019cites this paper
• Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial.

  2014cites this paper